The Clinical Core of the Pacific Northwest (PNW) Prostate Cancer SPORE will support multiple areas relevant to clinical research, including independent clinical research trials spawning from the Major Projects, biospecimen acquisition, a repository for clinical data, and advocacy activities. Specifically, the 4 major aims are:
Specific Aim 1 : To design, execute, accrue to, and othen/vise facilitate the conduct and timely completion of clinical trials relevant to the Major SPORE projects and cores. Clinical investigators from the University of Washington (UW), the University of British Columbia (UBC), and Oregon Health and Science University (OHSU) will participate in this aspect of the core. New clinical trials are planned specific to Projects 2, 3, 4, and 5. There is a renewed effort to improve minority awareness and accrual to these clinical trials.
Specific Aim 2. To design, direct, and assist in patient recruitment for biospecimen acquisition. Specifically, this will support the logistical aspects of consenting patients and actual acquisition of the biospecimens, including emphasis on patient accrual to the rapid tumor autopsy program.
Specific Aim 3. To continue to direct, support, and enhance CAISIS, our repository of clinical and patient-reported data to support clinical and translational prostate cancer research across the consortium. Key initiatives include Improving the efficiency of data collection, the quality and completeness of the data, and the ability to share data with other investigators and other SPOREs in prostate cancer. We will ensure access to CAISIS data for research across PNW SPORE sites.
Specific Aim 4. To ensure that SPORE Major and Developmental Projects maintain a patient-centered focus, we will support and engage the SPORE Advocacy Committee in the activities of the SPORE. The Advocacy Committee will aid in increasing dissemination of information in regards to clinical trials to prostate cancer support groups and minority patient populations. Advocacy Committee members will set research priority areas that influence selection of funded Developmental Projects.

Public Health Relevance

The Clinical Core is essential to conducting translational clinical research and accomplishing SPORE project aims. In addition, our data repository, CAISIS, will provide ongoing outcomes data that annotate specimens in the Biospecimen Core. These specimens, although useful in and of themselves, have increased value when there is detailed information about prior therapies, patterns of disease, and outcomes.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Program Officer
Hruszkewycz, Andrew M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
Zhang, Ailin; Zhang, Jiawei; Plymate, Stephen et al. (2016) Classical and Non-Classical Roles for Pre-Receptor Control of DHT Metabolism in Prostate Cancer Progression. Horm Cancer 7:104-13
Uo, T; Dvinge, H; Sprenger, C C et al. (2016) Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain. Oncogene :
Faltermeier, Claire M; Drake, Justin M; Clark, Peter M et al. (2016) Functional screen identifies kinases driving prostate cancer visceral and bone metastasis. Proc Natl Acad Sci U S A 113:E172-81
Lam, Hung-Ming; McMullin, Ryan; Nguyen, Holly et al. (2016) Characterization of an abiraterone ultraresponsive phenotype in castration-resistant prostate cancer patient-derived xenografts. Clin Cancer Res :
Saranchova, Iryna; Han, Jeffrey; Huang, Hui et al. (2016) Discovery of a Metastatic Immune Escape Mechanism Initiated by the Loss of Expression of the Tumour Biomarker Interleukin-33. Sci Rep 6:30555
Qu, Xiaoyu; Jeldres, Claudio; Glaskova, Lena et al. (2016) Identification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence. J Mol Diagn 18:215-24
Gulati, Roman; Cheng, Heather H; Lange, Paul H et al. (2016) Screening men at increased risk for prostate cancer diagnosis: Model estimates of benefits and harms. Cancer Epidemiol Biomarkers Prev :
Shui, Irene M; Kolb, Suzanne; Hanson, Christi et al. (2016) Trichomonas vaginalis infection and risk of advanced prostate cancer. Prostate 76:620-3
Coleman, Daniel J; Van Hook, Kathryn; King, Carly J et al. (2016) Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. Oncotarget 7:40690-40703
Pritchard, Colin C; Mateo, Joaquin; Walsh, Michael F et al. (2016) Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med 375:443-53

Showing the most recent 10 out of 323 publications